Table 5.
Selected clinical trials for mtKRAS tumors
| Drug | Target(s) | Phase | Identifier* |
|---|---|---|---|
| Bortezomib | Proteasome | II | NCT01833143 |
| VS-6063 | FAK | II | NCT01951690 |
| AZD6244 | MEK | II | NCT01306045 |
| GI-4000 | mtKRAS | II | NCT00655161 |
| IPI-504 | Hsp90 | NCT01427946 | |
| Everolimus | MTOR | I/II | |
| MEK162 | MEK | I | NCT01337765 |
| BEZ235 | PI3K/AKT | ||
| PD-0325901 | MEK | I/II | NCT02022982 |
| PALBOCICLIB | CDK4/6 | ||
| MEK162 | MEK | I/Ib | NCT01859026 |
| Erlotinib | EGFR | ||
| Trametinib | MEK | Ib/II | NCT02079740 |
| Navitoclax | BCL2/BCLXL | ||
| MEK162 | MEK | I/Ib | NCT02185690 |
| Carboplatin | DNA damage | ||
Note:
*
Identifier from ClinicalTrials.gov.
Abbreviations: mtKRAS, activating KRAS mutations; Hsp90, heat shock protein 90; MTOR, mammalian target of rapamycin; PI3K, phosphatidylinositol 3-kinases; CDK, cyclin-dependent kinase; EGFR, epidermal growth factor receptor.